Maestros Electronics & Telecommun. Systems Ltd
Incorporated in 2010, Maestros Electronics & Telecommunications Systems Ltd is in the business of Electronics & Instrumentation (E&T) and Telemedicine[1]
- Market Cap ₹ 76.4 Cr.
- Current Price ₹ 139
- High / Low ₹ 185 / 106
- Stock P/E 10.1
- Book Value ₹ 76.5
- Dividend Yield 0.00 %
- ROCE 23.9 %
- ROE 19.6 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
- Debtor days have improved from 97.4 to 75.4 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Industrials Capital Goods Industrial Manufacturing Industrial Products
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 33.29 | 28.89 | 39.43 | |
| 27.37 | 24.77 | 31.82 | |
| Operating Profit | 5.92 | 4.12 | 7.61 |
| OPM % | 17.78% | 14.26% | 19.30% |
| 2.24 | 2.44 | 2.28 | |
| Interest | 0.80 | 0.48 | 0.39 |
| Depreciation | 0.45 | 0.39 | 0.48 |
| Profit before tax | 6.91 | 5.69 | 9.02 |
| Tax % | 28.51% | 23.20% | 19.51% |
| 4.94 | 4.37 | 7.25 | |
| EPS in Rs | 8.97 | 7.93 | 13.16 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 36% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 72% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 16% |
| 3 Years: | 30% |
| 1 Year: | -4% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 17% |
| Last Year: | 20% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 5.51 | 5.51 | 5.51 |
| Reserves | 25.02 | 29.36 | 36.65 |
| 5.35 | 3.60 | 1.62 | |
| 21.39 | 20.56 | 20.77 | |
| Total Liabilities | 57.27 | 59.03 | 64.55 |
| 8.21 | 9.00 | 9.89 | |
| CWIP | 3.71 | 5.59 | 6.39 |
| Investments | 0.00 | 0.00 | 0.00 |
| 45.35 | 44.44 | 48.27 | |
| Total Assets | 57.27 | 59.03 | 64.55 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 7.25 | 5.69 | 1.75 | |
| -7.02 | -5.17 | -0.83 | |
| -0.24 | -0.39 | -0.77 | |
| Net Cash Flow | -0.01 | 0.12 | 0.16 |
| Free Cash Flow | 3.34 | 2.61 | -0.38 |
| CFO/OP | 145% | 183% | 39% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 172.36 | 44.35 | 75.44 |
| Inventory Days | 359.80 | 494.60 | 67.50 |
| Days Payable | 236.18 | 296.92 | 44.73 |
| Cash Conversion Cycle | 295.98 | 242.02 | 98.22 |
| Working Capital Days | -35.96 | -65.57 | -9.44 |
| ROCE % | 16.65% | 23.88% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Employees Count ・Standalone data |
|
||||||||||
| Telemedicine Segment Revenue Contribution % ・Standalone data |
|||||||||||
| Revenue Expenditure on R&D Rs. Lakhs ・Standalone data |
|||||||||||
| Purchase Orders Received - ECG Machines Units ・Standalone data |
|||||||||||
| Purchase Orders Received - Health Kiosks Units ・Standalone data |
|||||||||||
| Purchase Orders Received - Multipara Monitors Units ・Standalone data |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1 Jun - Copy of newspaper publication dated May 31, 2026 in the following newspapers with respect to Audited Financial Results for the Quarter and Financial Year ended …
-
Announcement under Regulation 30 (LODR)-Change in Management
29 May - Board approved FY26 standalone and consolidated audited results with unmodified opinion and appointed ABHL & Associates internal auditor.
- Audited Standalone And Consolidated Financial Results For The Quarter And Financial Year Ended March 31, 2026 Along With Auditor'S Report Issued By Statutory Auditors Of The Company. 29 May
-
Board Meeting Outcome for Outcome Of The Board Meeting Of The Company Held Today I.E. May 29, 2026
29 May - Board approved FY26 audited standalone and consolidated results on May 29, 2026; unmodified audit opinion, appointed internal auditor.
-
Board Meeting Intimation for Intimation Of The Board Meeting Under Regulation 29 Of SEBI (LODR) Regulations, 2015('Listing Regulations')
25 May - Board meeting on May 29, 2026 to approve FY26 audited results and financial statements.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
Business Overview:[1]
Company is a design, development and manufacturing company which creates
products and services for financial inclusion, cardiology, gynecology, critical care patient
and diseases management in medicine. It specializes in Medical device manufacturing, Telemedicine and Healthcare Solutions and Business Automation (Banking and Micro finance, financial inclusion, PDS automation)